Rational therapy of candidous vulvovaginitis in pregnancy

Abstract

Objective of the study: was to evaluate the efficacy and safety of the Clofan® drug (clotrimazole, vaginal suppositories 500 mg) for treatment of candidiasis vulvovaginitis (CVV) in the third trimester with multiple pregnancy after using assisted reproductive technologies. Materials and methods. 32 women with multiple pregnancies were examined after using assisted reproductive technologies with CVV symptoms in the third trimester. General clinical research methods, vaginal smear microscopy, and culture studies using culture media were used to confirm the diagnosis. Spores and yeast fungal cells were isolated by smear microscopy of vaginal contents in all women. Examination was carried out before treatment, 1 week and 4 weeks after treatment. A single intravaginal suppository Clofan® 500 mg was used at night. Results. 7 days after Clofan® use clinical recovery was observed in 30 (93.8%) patients, and a significant symptoms reduction in 2 (6.2%) patients. Elimination of concomitant pathogenic and conditionally pathogenic bacterial microflora was achieved in 27 patients (84.4%). The absence of Candida albicans DNA in vaginal secretion after treatment was also noted in 27 patients (84.4%). The threat of preterm birth was observed in 2 cases (6.2%), premature discharge of amniotic fluid in 3 (9.4%) cases, candidal postpartum endometritis and joint discrepancy in the postpartum period were absent in all cases. Conclusions. The study showed the high efficiency of Clofan® in the treatment of CVV in the III trimester in multiple pregnancy after assisted reproductive technologies. This helped to reduce the frequency of the threat of premature birth, premature discharge of amniotic fluid and postpartum complications. Clofan® is an effective and safe topical preparation for CVV, and it also has a pronounced therapeutic effect on gram-positive bacteria and anaerobes. A low incidence of side effects against the background of its use was found.